



**TODAY'S HIGHLIGHTS**

**Plenary Session: Immunology in Lung Cancer Update 2017**

8:15-9:45

Plenary Hall (Exhibit Hall D)

**Mini Symposium: Being Mortal: Learning from ZEN**

11:00-12:30 • Room 316

**Mini Symposium:**

**The Cost of Lung Cancer**

11:00-12:30 • Room 502

**Educational Session: Recent Advances in Diagnostics and Interventional Bronchoscopy**

11:00-12:30 • Room 503

**Mini Symposium: Engaging Patients in Research: Best Practices**

14:30-16:15 • Room 311 + 312

**Educational Session: Recent Progress in the Management of Small Cell Lung Cancer**

14:30-16:15 • Room 501

**Educational Session: Radiation Treatment Update**

14:30-16:15

F201 + F202 (Annex Hall)

**Closing Plenary: Where We Are Now, and Where We Will Be in 10 Years**

16:30-17:45 • Main Hall

**INSIDE THIS ISSUE**

Giving Ceritinib with Meals Can Mitigate GI Side Effects	4
Plenary Session Focuses on Advances in Immuno-oncology	6
Molecular Testing in Lung Cancer Moves Forward	8
Wednesday Sessions Focus on Liquid Biopsy	10
What Does the Future Hold?	12
See You in Toronto	13
Ado-trastuzumab Emtansine for the Treatment of HER2-mutant Lung Cancers	14
IASLC Research Awards	14
New IASLC Reference Provides Valuable Resource to Thoracic Clinicians	15
Question of the Day	16

## Top Three Abstracts Discussed at Presidential Symposium

By *Cynthia L. Kryder, MS*

The Presidential Symposium on Tuesday morning recognized the authors of three exceptional abstracts submitted to WCLC 2017.

### Patient-reported Outcomes from the PACIFIC Trial

According to previously reported efficacy and safety results of the PACIFIC trial, patients receiving durvalumab had a significant improvement in progression-free survival (16.8 months vs. 5.6 months) (see Figure 1 on page 2), and a lower incidence of new lesions, including new brain metastases, compared with patients receiving placebo after definitive chemoradiation therapy for locally advanced NSCLC. Additionally, durvalumab was well tolerated with a manageable safety profile. In Tuesday's session, Rina Hui, MBBS, FRACP, PhD, Crown Princess Mary Cancer



Rina Hui, MBBS, FRACP, PhD

Centre, Westmead, Australia, presented additional data on patient-reported outcomes, a secondary endpoint of the PACIFIC trial, a randomized, placebo-controlled, double-blind, phase III study in locally advanced, unresectable NSCLC.

see [Presidential Symposium](#), page 2

## Community Engagement Program Designed to Reduce Lung Cancer Disparities

By *Lori L. Alexander, MTPW, ELS, MWC®*

Disparities in lung cancer exist among racial/ethnic minorities and the medically underserved. A study to be presented on Wednesday addresses this issue with the use of a specialized educational program to improve cancer health literacy and outcomes in disparate populations.

The authors evaluated the effect of cancer-Community Awareness Access Research & Education (c-CARE), a program designed to increase community awareness of lung cancer risk factors and screening criteria.

"Minority and medically underserved populations are less likely than others to adopt new cancer screenings,"



Lovoria B. Williams, PhD, APRN-BC, FAANP

explains Lovoria B. Williams, PhD, APRN-BC, FAANP, Georgia Cancer Center, Augusta University, Augusta, USA, who will present the findings.

see [Community Engagement](#), page 9



## Ado-trastuzumab Emtansine for the Treatment of *HER2*-mutant Lung Cancers

**H**uman epidermal growth factor receptor 2 (*HER2*, *ERBB2*) mutation and amplification each occurs in 2% of lung cancers, resulting in receptor dimerization and oncogenic signaling with in vitro sensitivity to trastuzumab. Ado-trastuzumab emtansine is a *HER2*-targeted antibody drug conjugate linking trastuzumab with the anti-microtubule agent emtansine. This morning,

Bob T Li, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, USA, will present the results of research demonstrating that ado-trastuzumab was active and well tolerated in patients with advanced *HER2*-mutant or amplified lung cancers.

Dr. Li will report the overall response rates, progression-free survival, and

### New Paradigms in Clinical Trials

Oral Session 14

11:00-12:30 | Room 311 + 312

toxicities for 18 patients in the first *HER2*-mutant cohort. He notes that while cohort expansion is ongoing, this study met its primary endpoint in patients with *HER2*-activating mutations. ●



## IASLC Research Awards Encourage Innovative Research

**E**leven young researchers have received awards through the IASLC Fellowship Award Program, which is designed to recognize scientific excellence and encourage innovative research in lung cancer prevention and translational medicine worldwide. This year's awards comprise Fellowship Awards, Young Investigator Awards, the IASLC/Lung Cancer Foundation of America Fellowship Award, the IASLC/Boehringer Ingelheim Chinese Research Fellowship Award, the Bonnie J. Addario Lung Cancer Foundation/IASLC Award, and the IASLC/Prevent Cancer Foundation/Richard C. Devereaux Fellowship Award.

Applications for Fellowship and Young Investigator Awards are accepted each January. The applications are evaluated by the IASLC Career Development and Fellowship Committee for their merit, innovation, and potential impact on the management of lung cancer. ●

### 2017-2018 IASLC Fellowship Award

**Atiqur Rahman, PhD**, *University of Newcastle, Australia*

Project: Cell-free microRNA: A Potential Biomarker for the Early Detection of Lung Cancer

**Masaoki Ito, PhD**, *The Health Sciences Research Institute of the Germans Trias I Pujol Foundation, Barcelona, Spain*

Project: Exploring the Potential Oncogenic Role of the p21-Activated Kinase 1 (PAK1): A Novel Approach for Personalized Therapy in Non-small Cell Lung Cancer

**Hou-Fu Guo, PhD**, *The University of Texas MD Anderson Cancer Center, Houston, USA*

Project: Structural Insights into a Pro-metastatic Collagen Lysyl Hydroxylase

### 2017-2018 Young Investigator Award

**Paolo Ceppi, PhD**, *Interdisciplinary Center for Clinical Research (IZKF), University of Erlangen-Nuremberg, Erlangen, Germany*

Project: The Role of Thymidylate Synthetase in Epithelial-to-Mesenchymal Transition in Non-small Cell Lung Cancer

**William Lockwood, PhD**, *British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada*  
Project: Therapeutic Strategies and Mechanisms of Resistance in Lung Adenocarcinomas Driven by MET Splice-Site Mutations

**Pedro Medina Vica, PhD**, *University of Granada, Granada, Spain*  
Project: New Therapies for Lung Cancer Based on Gene-Editing Technologies

### 2017-2018 IASLC/Lung Cancer Foundation of America Fellowship Award

**Carla Martins, PhD**, *University of Cambridge, Cambridge, UK*  
Project: Exploiting the Metabolic Heterogeneity of Mutant Kras Lung Tumours to Optimize Therapy

**Kellie Smith, PhD**, *Johns Hopkins University, Baltimore, USA*

Project: Neoantigen Targeting in Patients with Early Stage NSCLC Receiving Neoadjuvant Nivolumab

### 2017-2018 IASLC/Boehringer Ingelheim Chinese Research Fellowship Award

**Deshui Jia, PhD**, *Fred Hutchinson Cancer Research Center, Seattle, USA*  
Project: Using Mouse Models to Study Roles for CREBBP as a Small Cell Lung Cancer Tumor Suppressor

**Shengxiang Ren, PhD**, *Shanghai Pulmonary Hospital, Shanghai, China*  
Project: Early Diagnosis in Lung Cancer

### 2017-2019 Bonnie J. Addario Lung Cancer Foundation/IASLC Award

**Evgeny Izumchenko, PhD**, *Johns Hopkins University, Baltimore, USA*  
Project: Comprehensive Analysis of the Genetic Landscape during Progression of Non-small Cell Lung Adenocarcinoma

### 2016-2017 IASLC/Prevent Cancer Foundation/Richard C. Devereaux Fellowship Award

**Valsamo Anagnostou, MD, PhD**, *Johns Hopkins University, Baltimore, USA*  
Project: Comprehensive Genomic Analysis for Early Detection of Recurrence and Therapeutic Intervention in Stage I/II Non-small Cell Lung Cancer